Previous 10 | Next 10 |
Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders Canada NewsWire TSX: ASND www.ascendantresources.com All matters overwhelmingly approved by shareholders TORONTO , Aug. 23, 2023 /CNW/ - Ascendant Resource...
COPENHAGEN, Denmark, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2023 financial results and provide a business update on Tuesday, September 5, 2023, after the close of the U.S. financial markets. Ascendis Pharma will also host...
2023-07-26 07:00:00 ET Summary Baron Health Care Fund invests in companies engaged in the research, development, production, sale, delivery, or distribution of products and services related to the healthcare industry. In the quarter ended June 30, 2023, Baron Health Care Fund adva...
2023-07-11 09:07:01 ET Summary Ascendis Pharma's TransCon PTH drug faced FDA rejection due to manufacturing control concerns, but not clinical data. Discussions with the FDA and a European decision in Q4 2023 are planned. Q1 2023 revenue: $36.96 million, primarily from Skytrofa sa...
2023-06-30 09:15:22 ET Summary Ngenla, a long-acting medicine for treating children with growth hormone deficiency, has been approved by the FDA for use in the United States, adding to its presence in over 40 countries. Pfizer Inc. and Opko Health have been jointly developing and ...
- Oral presentation of results showed sustained improvements through Week 52, as well as safety and tolerability similar to that previously reported for the initial 26-week blinded portion of the Phase 3 PaTHway Trial - At Week 52, 95% of patients treated with TransCon PTH achieve...
- Endocrinology clinical development progress and research i n growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome will be highlighted - Phase 3 Week 52 data for TransCon ™ PTH in adults with hypoparathyroidism selected for o...
COPENHAGEN, Denmark, June 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs ...
– Compassionate use enables treating physicians in Germany to request access to investigational TransCon PTH (palopegteriparatide) for eligible adult patients with hypoparathyroidism COPENHAGEN, Denmark, June 05, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today annou...
2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...
News, Short Squeeze, Breakout and More Instantly...
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada Canada NewsWire MONTREAL , July 4, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distributio...
• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose • Improvements could not be explained by changes in linear growth only, supporti...
2024-06-19 21:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...